Twelve of the 15 analysts surveyed by S&P Global ( SPGI +1.32%) in April rated the pharmaceutical stock as a "buy" or "strong ...

Following a quiet stretch, the legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva ...

If you are wondering whether Teva Pharmaceutical Industries at around US$31.22 still offers value or is looking stretched, ...

The Federal Circuit reversed a ruling that had wiped out Teva Pharmaceuticals International GmbH’s $177 million Ajovy patent ...

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival ...

The Class II recall covers 3 dosages of clonidine transdermal patches made by Actavis Laboratories, with no adverse health ...

TEL AVIV (Reuters) -Teva Pharmaceutical Industries will remain a single company for generic and branded drugs, and expects to see significant interest in its active pharmaceutical ingredients business ...

Viatris and Teva Pharmaceutical Industries recently launched separate recalls in the U.S. related to dissolution problems for ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is featured on the David Einhorn Stock Portfolio: Top 10 Stock Picks. Teva ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came from leading medications like Austedo, which improved its sales by 38% year ...

Israel’s Teva Pharmaceutical Industries has teamed up with NeuroGen Pharma to jointly promote the wide availability of ...